was used to examine and compare the validity, reliability, and convergence of patient and parent responses on QoLISSY in the field test dataset, and to predict QoLISSY scores from clinical, socio-demographic and psychosocial variables. Results: Validity and reliability indicators were satisfactory for each sample after iteratively omitting one country. Comparisons with the total sample revealed cross-cultural equivalence in internal consistency and construct validity for patients and parents, high inter-rater agreement and a substantial proportion of QoLISSY variance explained by predictors. Conclusion: The TOCO technique is a powerful method to overcome problems of country-specific testing of patient-reported outcome instruments. It provides an empirical support to QoLISSY's cross-cultural equivalence and is recommended for future research. 
Introduction
Assessment of health-related quality of life (HrQoL) in children and adolescents is increasingly regarded as an important topic in paediatrics. Measures to assess HrQoL in young persons have been developed for population studies and for clinical studies of children with acute or chronic health conditions [1] .
A recent review of the paediatric literature shows that generic measures have primarily been used to assess child self-reported health. Instruments have also been targeted to children and adolescents with specific health problems [2, 3] . The psychological development of children with short stature and associated impairments in HrQoL, as well as the impact of growth hormone (GH) treatment has received substantial, however not unequivocal, attention in the literature [4] .
Using generic measures, several studies have not found differences in the HrQoL of children and adolescents with or without GH treatment, while others report more psychological impairment in GH treatment-naive patients with an achieved height of above -2 standard deviation (SD) as compared to GH-treated patients within the normal range for age and gender group [5] .
These results suggest that generic measures could be less sensitive for detecting subtle but clinically relevant changes in HrQoL and highlight the importance of including specific assessments in short stature. However, few instruments have been developed for conditions related to physical impairments, disabilities or handicaps, such as those associated with short stature. A literature review identified five condition-specific HrQoL measures in adolescents and children with short stature. Most of them, however, have been developed in one country or language context only, have not been translated to other cultural contexts, have not undergone linguistic validation and have not been subjected to cross-cultural psychometric testing [6] . This limits the ability to conduct rigorous cross-cultural research to evaluate outcomes from new treatment paradigms and precludes generalization of observed treatment effects beyond national borders.
The Quality of Life in Short Stature Youth (QoLISSY) project aimed at developing an instrument for short-statured children and adolescents with growth hormone deficiency (GHD) or idiopathic short stature (ISS) and their parents [4, 7] , responding to the necessity to cross-culturally develop an appropriate measure rather than relying on the translation of an instrument developed in just one country or language. The QoLISSY project respected the simultaneous approach to making HrQoL instruments available cross-culturally which aims at a common conceptual development of an instrument across several cultures and languages simultaneously [8] .
The international guidelines for the development of quality of life measures have been proposed which describe three steps to be taken to arrive at a cross-culturally valid instrument [8, 9] : (1) conducting focus groups with children/adolescents and parents in order to identify relevant domains and items and a conceptual model, (2) pilot testing with cognitive debriefing of the preliminary items of the measure, and (3) field testing with a retest of the instrument in children and one of their parents, in order to examine psychometric properties, namely validity and reliability.
The aim of the QoLISSY instrument development was to construct a psychometrically sound and cross-culturally valid tool that covers the impacts of short stature on HrQoL in children and adolescents from their own perspective and the added perspective of their parents [10, 11] . Development and psychometric testing of the QoLISSY instrument in a large sample of children and adolescents from five European countries (France, Germany, Spain, Sweden and the UK) were described in a previous paper [12] . The current paper specifically intends to employ a truly cross-cultural approach to instrument development and testing by iteratively omitting data from one country from the pooled dataset and comparing the resulting psychometric characteristics across the datasets. This 'take-one-country-out (TOCO) technique' aims at testing cross-cultural stability in instrument psychometric performance.
Methods

Participants and Procedures
The current analyses use data from the field test phase of the QoLISSY project. The sample consisted of short-statured patients in two age groups (children aged 8-12, and adolescents aged 13-18 years) and their parents, recruited from the collaborating growth clinics in France, Germany, Spain, Sweden and the UK. Recruitment focused on including subjects by diagnosis (GHD and ISS), treatment status (GH-treated and untreated), age (children and adolescents) and gender (boys and girls). Upon ethics committee approvals, informed consent from all parents and informal assent from children and adolescents were obtained, together with the permission to extract medical data from patients' charts through their clinicians at the study centres. Questionnaires were mailed to parents and children, in which, in addition to HrQoL assessments, socio-demographic, clinical and psychosocial information was collected. Distribution by mail was conducted through the growth centres to patients and parents separately with a prepaid return
The QoLISSY Questionnaire
The QoLISSY questionnaire is a condition-specific instrument to assess the patient-reported HrQoL of children and adolescents with short stature, aged 8-18 years as well as the parent-reported HrQoL of children aged 4-18 years. The questionnaire was simultaneously developed in five European countries using focus groups with item generation, a pilot test with cognitive debriefing and a field test with re-test.
The patient-and parent-reported version of the QoLISSY questionnaire, as applied in the field test phase, consists of a core module with 22 items, assessing three HrQoL domains: physical (6 items, e.g. 'Because of my height I depend on others.'), social (8 items, e.g. 'Because of my height I get laughed at or teased.') and emotional (8 items, e.g. 'I am happy with my height.'). Additionally three scales assessing determinants of HrQoL: coping (10 items, e.g. 'I tell myself it is okay to be short.'), height-related beliefs (4 items, e.g. 'I believe that tall people are better liked.') and treatment experiences (14 items, e.g. 'I feel good because of my treatment.') are included. The parent-reported version included two additional scales assessing concerns about the child's future (5 items, e.g. 'My child worries about whether (s)he will grow enough.') and the effects of their child's short stature on the family (11 items, e.g. 'My child's growth problems make me feel anxious.'). All items are to be answered with a 5-point Likert scale, whose interval properties had been examined in earlier research. Response options ranged from 1 (not at all/never) to 5 (extremely/ always) considered the 'past week' as time reference. Standardized (0-100) scores were computed for each scale separately, and summed up to a total score of HrQoL representing the three scales of the core domain [12] . The QoLISSY instrument is freely available for academic use. Access to the instrument is provided upon request through a published manual, webpages and individual orders (see information at the end of this article).
Data Analyses
Statistical analyses of field test data were performed with the Statistical Package for the Social Sciences version 18.0 (SPSS, Inc., Chicago, Ill., USA) and with the Analysis of Moments Structures, version 18 (AMOS). Descriptive statistics were calculated for socio-demographic and clinical variables. Scale scores were calculated if less than 25% of responses were missing. The homogeneity of the sample's characteristics across countries was tested by χ 2 test and analysis of variance (ANOVA) with post hoc tests, depending on whether the variable was categorical or continuous.
Second-order confirmatory factor analyses (CFA) were performed to examine the factorial structure of the patient-reported and parent-reported version of the QoLISSY questionnaire. The second-order CFA model comprised 6 observed indicators (i.e. 6 items) loading on the physical domain, 8 observed indicators loading on the social domain, and 8 observed indicators loading on the emotional domain; in turn, the three domains loaded on a HrQoL total score. The models' goodness of fit was assessed using the main fit indexes: maximum-likelihood χ 2 p value and χ 2 /degrees of freedom (d.f.), comparative fit index (CFI), root mean square error of approximation (RMSEA), and standardized root mean squared residual (SRMR). The reference values of χ 2 /d.f. ≤ 2, CFI ≥ 0.95, RMSEA ≤ 0.06 and SRMR ≤ 0.08 were considered indicators of the model's good fit to the data, and the reference values of χ 2 /d.f. ≤ 5, CFI ≥ 0.90 and RMSEA ≤ 0.10 were considered the threshold for assessing the model's fit as acceptable [13] [14] [15] .
Given the small sample size in each country separately, the measurement invariance of the factorial model across the five countries was tested using multi-group analyses with the TOCO approach. This technique consists of comparing the psychometric results and the socio-demographic, clinical and psychosocial determinants of HrQoL between the total sample from the five participating countries and subsamples. From the total sample of five countries, one was removed at a time and results were compared. The χ 2 difference method (Δχ 2 ) was used to compare the unconstrained model with a model in which factor loadings (measurement invariance) and structural weights (structural invariance) were constrained to be equal across groups [16] .
Once a factorial structure had been identified for both, the patient-and parent-reported version of the QoLISSY questionnaires, its psychometric properties were further analysed for each country independently and for the subsamples removing one country at a time. Reliability of the QoLISSY subscales and total score was assessed by using the Cronbach's α value and the composite reliability value, calculated from the squared sum of standardized factor loading divided by the squared sum of standardized factor loading plus the sum of the error variance terms. Good construct reliability was established if composite reliability was >0.70 [17] .
Agreement between patients' and parents' reports across different countries was examined using intraclass correlation coefficients (ICCs) (two-way mixed model, absolute agreement, 95% confidence interval). The levels of agreement were calculated for each country independently and for the subsamples, again by TOCO. By transforming the correlation coefficients in Z -Fisher scores [13] , the levels of agreement of each subsample were compared with the total sample.
To identify the determinants of HrQoL total score, hierarchical multiple regression analyses were performed with two different approaches for the cross-cultural analyses. First, a regression analysis for the total sample was conducted, including the 'country' as a predictor, after this categorical variable had been recoded into dummy variables. Second, the regression analyses were conducted for the TOCO subsamples. To minimize the effect of sample dissimilarities across countries, socio-demographic and clinical characteristics were controlled by including them in the first block of the regression equation. Children's and parents' HrQoL determinants (coping, beliefs and treatment experiences) were entered in the second block. A third block was added only for the parent report including the two supplementary determinants for parents (future of the child and effects on parents).
Results
Sample Characteristics
A total of 268 children and adolescents with short stature, aged between 8 and 18 years, and one of their parents were included in the QoLISSY field test used for the current analyses. An overview of socio-demographic and clinical characteristics of the samples per country is displayed in table 1 .
The frequency distribution of gender and diagnosis was homogeneous across countries for the patient sample. Sweden, however, had recruited a larger number of adolescents as compared to other countries. The distribution of treatment status and height deviation also differed across countries, with higher percentages of untreated children in France and Spain, and higher percentage of children with height deviation above -2 SD in France. Significant differences in the parents' socio-demographic characteristics across countries were found: the Spanish sample included more fathers or both parents; regarding age, Swedish parents were older than parents from other countries.
Confirmatory Factor Analysis and Reliability of the QoLISSY Patient-Reported Version
The second-order CFA model of the patient-reported version of the QoLISSY questionnaire had an acceptable fit, with χ 2 (206, n = 263) = 615.35, p < 0.05, χ 2 /d.f. = 2.99, CFI = 0.88, RMSEA = 0.087 and SRMR = 0.054. All items showed factorial validity, with significant factor loadings (p < 0.001) and, except for two items, standardized regression weights were above the threshold of 0.50. Using the TOCO approach, the factorial model was re-run for the five subsamples, sequentially removing the data from one country at a time. As presented in table 2 , the secondorder CFA model had an acceptable fit for the five TOCO subsamples. The results from multi-group analyses showed no significant χ 2 differences in factor loadings and structural weights between the total sample and the TOCO subsamples in which one country was removed, confirming the measurement and structural invariance of the structural model across countries.
Inspection of the reliability of the three core domains (physical, social and emotional) and of the total score showed acceptable Cronbach's α values [14, 15] for each country independently (ranging from 0.72 to 0.96) and for the total sample removing one country at a time (ranging from 0.83 to 0.95) ( table 3 ) . Additionally, the composite reliability values for the TOCO subsamples were higher than the threshold of 0.70 [17] , indicating good reliability for the subscales and for the HrQoL total score.
Confirmatory Factor Analysis and Reliability of the QoLISSY Parent-Reported Version
The factorial model for the parent-reported version of the QoLISSY questionnaire was built in strict equivalence to the patient-reported version. The model had an accept- ( table 4 ) . The second-order CFA model had an acceptable fit for the TOCO subsample in which Spanish data were removed, and a nearly acceptable fit for the remaining TOCO subsamples. The absence of significant χ 2 differences in the factor loadings and structural weights between the total sample and the TOCO subsamples indicates that the factorial structure of the parent-reported version of the QoLISSY questionnaire was invariant across countries.
High internal consistency values were observed for all three core domains and HrQoL total score for each country independently (Cronbach's α values ranging from 0.78 to 0.96). Moreover, very good Cronbach's α's (ranging from 0.83 to 0.96) and composite reliability values (ranging from 0.85 and 0.97) were found for the five TOCO subsamples where one country was sequentially removed ( table 5 ) .
Agreement between Patients' and Parents' Reports
Moderate to strong levels of agreement were found between children/adolescents' and parents' reports on the QoLISSY HrQoL domains and total score for all countries independently (ICCs ranging from 0.58 to 0.80) and for the TOCO subsamples (ICCs ranging from 0.66 to 0.78). These high levels of agreement across countries supported the cross-cultural concurrent validity of the QoLISSY instruments ( table 6 ) .
Determinants of HrQoL in Short Stature
The QoLISSY additional modules (coping, beliefs and treatment as patient-reported HrQoL determinants; coping, beliefs, treatment, future and effect on parents as parent-reported HrQoL determinants) presented good reliability coefficients, with Cronbach's α values ranging from 0.77 (coping) to 0.91 (treatment) for the children/ adolescents' reports, and from 0.72 (coping) to 0.96 (beliefs) for the parents' reports ( table 7 ) .
To identify the determinants of HrQoL, we conducted hierarchical regression analyses for the total sample, entering socio-demographic (age group, gender and country), and clinical (diagnosis, treatment status, current height deviation) characteristics in the first block, and psychosocial determinants as assessed by the QoLISSY additional subscales in the second (coping, beliefs and treatment experiences) and third (future and effects on parents; only for parent-reported data) block of the regression equation. The regression model explained 59% of the patient-reported HrQoL variance and 72% of the parent-reported HrQoL variance ( table 8 ) .
Socio-demographic and clinical characteristics explained 28% of the patient-reported and 32% of the parent-reported HrQoL variance. Here height deviation was the variable with the greatest individual contribution, in- 25 dicating a negative association between current short stature and HrQoL, both patient-and parent-reported. No significant country effects were found for patient-reported HrQoL. For parent-reported HrQoL, having Swedish nationality was associated with better HrQoL. Controlling for socio-demographic and clinical characteristics, HrQoL determinants explained 32% of patientreported and 25% of parent-reported HrQoL. Specifically, adaptive general beliefs about height were positively associated with better patient-and parent-reported HrQoL. The two extra HrQoL determinants included in the parent version additionally explained 16% of variance in parent-reported HrQoL: fewer worries about the child's future and a lesser effect of growth problems on parents' feelings were significantly linked to higher parental ratings of the child's HrQoL.
Regression analyses re-run for the TOCO subsamples showed consistent results across countries. For patientreported HrQoL, the proportion of variance explained by socio-demographic and clinical characteristics together with HrQoL determinants ranged from 52 to 61% across countries ( table 9 ). As with the results for the total sample, height deviation and beliefs presented significant individual contributions in all TOCO subsamples: current height deviation >-2 SD (achieved normal height) and more adaptive beliefs about stature were associated with better patient-reported HrQoL.
For the parents' reports of their children's HrQoL, clinical and socio-demographic variables and the QoLISSY determinants explained between 59 and 75% of the variance across the TOCO subsamples ( table 10 ) . Significant individual contributions of the current height deviation, beliefs about stature, worries about the future and effects on parents were consistently found for the total sample and for all TOCO subsamples. In addition, treatment experiences also had a significant effect on parentreported HrQoL in four of the five TOCO subsamples. Specifically, and except when the UK was taken out, more positive treatment experiences were associated with better parent-reported HrQoL. Fewer worries about the child's future and reduced impact of the growth problems on parents were also associated with better parent-reported HrQoL, explaining an additional portion of HrQoL variance ranging from 15 and 35% across TOCO subsamples.
Discussion
Using a simultaneous strategy in instrument development across countries makes it possible to incorporate cross-cultural input from the outset of the process and provides insight into similarities and differences between countries with respect to perceptions and evaluations of the HrQoL concept.
The QoLISSY project simultaneously developed a condition-specific questionnaire for children and adolescents with short stature and their parents. Researchers and clinicians from five countries cooperated to create a 27 quality of life measure through a systematic qualitative and quantitative process involving focus groups (for item generation and formation of the conceptual model), a pilot test (for preliminary analysis and cognitive debriefing of items and scales) and a field test with retest (with final psychometric analysis of instrument performance across all countries) yielding rich information about the assessment of HrQoL of children. The present paper examined the last of these steps with regard to the cross-cultural psychometric performance of the QoLISSY core module and its determinant modules from field test data. The process respected lessons learned from one of the first international HrQoL instrument development exercises: the World Health Organization (WHO) quality of life measure: the WHO-QoL [18] .
One major issue in the analysis of a cross-cultural dataset is the choice of the strategy used to derive psychometric information [19] . Analyses conducted on the international level involving all countries cannot be easily broken down to the individual countries both for reasons of sample size as well as sample composition. Between 5 and 10 respondents per item would be necessary to conduct principal component factor analysis on a country level. Especially in rare health conditions, such as GHD, and limited patient samples, such as healthreferred ISS patients, it is difficult to recruit a sufficient number of participants into a study. Therefore, the use of sophisticated psychometric strategies such as CFA with structural equation modelling, requiring larger sample sizes, is usually not possible on the single-country level.
One alternative strategy is to use a combined international total dataset, then remove subsequently and iteratively one country at a time and examine the correspondence between the resulting models. This TOCO strategy was chosen for testing the QoLISSY questionnaire, after having examined and taken into account differences in the sample composition across countries.
CFA of the patient-reported combined QoLISSY dataset showed that the factorial model including physical, social and emotional quality of life with a global score had an acceptable fit. Within the TOCO approach, CFA results, as indicators of construct validity, remained stable after iteratively omitting one country. Fit indices were comparable across countries and comparisons of each dataset with the total dataset did not yield statistically significant differences, suggesting cross-cultural comparability in terms of factorial validity. Reliability was inspected for each country individually as well as following the iterative TOCO approach. Results showed good overall reliability with high convergence of coefficients between individual countries as well as good comparability between the TOCO and total datasets.
Similarly, the parent-reported version, subjected to CFA and reliability testing, yielded acceptable overall fit indices for the factorial model. Comparisons of each iterative TOCO dataset with the total dataset did not yield substantial differences.
Convergence of children's/adolescents' and parents' reports was supported using both individual countries and TOCO subsample ICCs. The moderate to high levels of parent-child agreement in assessing paediatric HrQoL found in the present study were in line with previous research reporting higher levels of agreement between parents and children with chronic health conditions than between parents and healthy children [20] . Moreover, Upton et al. [21] advocated that the levels of agreement would be dependent on the relevance of different domains for a specific clinical group. Since parent and children completed their field test questionnaires at home, a parental influence on children's answers cannot be ruled out. As the QoLISSY questionnaire is a disease-specific measure, the high levels of agreement may be explained by the pertinence of its items for the particular group of children with short stature and by the higher likelihood of parents to be more alert to the condition-specific is- sues, than to general aspects of HrQoL. Lack of significant differences in the level of agreement suggested cross-culturally comparable correspondence between parents' and children's ratings [22] .
Predictor models of HrQoL which include clinical, socio-demographic and psychosocial characteristics were tested. A hierarchical regression was performed for the total dataset and for the TOCO subsamples. Since sample characteristics differed across countries, age and treatment were included as covariates in the analysis. Even though fit statistics were not optimal in all tests, the resulting models explained similar proportions of HrQoL variance across countries, suggesting again that the QoLISSY instrument performance across countries is promising.
This was also true for the QoLISSY determinant modules, additionally included in regression models to predict HrQoL total scores. Regression results indicated a large contribution of psychosocial determinants to the proportion of variance, which was already well explained by socio-demographic and clinical factors. Interestingly, including country as dummy variable in the regression predicting both patient-and parent-reported HrQoL did not alter the results, supporting again the cultural invariance of the QoLISSY tool identified within the TOCO approach. In order to test the responsiveness of the measure to psychosocial or endocrine interventions, longitudinal studies, best randomized clinical trials, are needed.
The TOCO approach chosen proved to be a helpful and transparent technique to examine the cross-cultural equivalence of patient-reported outcome measures, which can serve as an alternative to repeated psychometric analysis in each national sample. It assumes that if taking one country out of the total dataset does not lead to significant changes in psychometric performance, this suggests cross-cultural comparability of the measure. However, if sufficient sample sizes can be reached in individual countries, the cross-cultural equivalence of the measure should additionally be assessed in a countrywise fashion, so that the psychometric performance can be critically examined comparing the TOCO approach to the sequential country-wise procedure.
A word of caution is necessary regarding the parent and patient sample included in the QoLISSY field test. Recruitment was at the discretion of participation clinics with the possible consequence of a selection bias and reduced generalizability of findings. Future studies should more clearly specify respective samples and recruitment procedures. They should also use longitudinal designs to investigate the responsiveness of the measure, within and across countries. This measure has been targeted to GHD and ISS patients because these conditions are primarily related to short stature and degree of GH deficiency is a common feature which is not the case with other conditions.
The QoLISSY project is an example for simultaneous cross-cultural instrument development in paediatric healthcare, ready to be included in epidemiological, clinical, health economic as well as quality assurance studies in Europe. The instrument has been tested for cross-cultural equivalence in five European countries so far, which share substantial societal commonalities. Extension of testing to other countries, especially outside of Europe, is ongoing and is expected to yield more information about variability or stability in QoLISSY's psychometric performance.
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